Side-by-side · Research reference

BronchogenvsRetatrutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED16/35 cited

BPhase 2HUMAN-REVIEWED10/41 cited

Bronchogen

Tetrapeptide Bioregulator · Khavinson-School

0.05 ng/mLEffective concentrationZakutskiĭ 2006

60 daysCOPD model durationTitova 2017

30 daysTreatment courseKuzubova 2015

Research models: tissue culture / parenteral

Retatrutide

Triple-receptor agonist · Phase 3

1–12 mgWeekly doseJastreboff 2023

24.2%Body-weight ↓Jastreboff 2023

~6 daysHalf-life (est)

SQ · Abdomen · Once weekly

01Mechanism of Action

Parameter

Bronchogen

Retatrutide

Primary target

Bronchial epithelial cellsKuzubova 2015

GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023

Pathway

Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration

Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023

Downstream effect

Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015 Titova 2017

Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023

Feedback intact?

—

Origin

Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework

Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023

Antibody development

—

02Dosage Protocols

Parameter

Bronchogen

Retatrutide

Effective concentration (culture)

0.05 ng/mLZakutskiĭ 2006

Demonstrated in organotypic tissue culture of bronchial explants.

—

Treatment duration (animal)

1 month (30 days)Kuzubova 2015 Titova 2017

Course duration in rat COPD models.

—

Evidence basis

Animal models (rat) / organotypic cultureTitova 2017 Kuzubova 2015 Zakutskiĭ 2006

No human clinical trials reported in available literature.

Phase 2 trial; Phase 3 ongoingJastreboff 2023

Model system

NO₂-induced COPD (60-day intermittent exposure)Titova 2017

—

Tissue specificity

Selective for bronchopulmonary tissue

Part of Khavinson organ-specific bioregulator series.

—

Standard dose

—

12 mg / week (max efficacy)Jastreboff 2023

Phase 2 trial dose. Phase 3 dosing TBD.

Frequency

—

Once weekly

Titration schedule

—

2 mg → 4 mg → 8 mg → 12 mg over 16 weeks

Duration

—

Indefinite for chronic indication (presumed)

Reconstitution

—

Investigational; not commercially available

Timing

—

Any time of day

Half-life

—

~6 days (estimated from class)

04Side Effects & Safety

Parameter

Bronchogen

Retatrutide

Animal safety profile

No adverse effects reported in published rat studies

Limited safety data; only animal models available.

—

Human data

Absent — no clinical trials in humans reported

—

Long-term effects

Unknown — maximum study duration 30 days in animals

—

GI symptoms

—

Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023

Heart rate

—

↑ resting HR (3–7 bpm at 12 mg)Jastreboff 2023

Glucose handling

—

Glycemic improvement; rare hyperglycemia from glucagon component

Pancreatitis risk

—

Class warning

Thyroid C-cell tumours

—

Class warning (presumed)

Pregnancy / OB

—

Avoid (insufficient data)

Absolute Contraindications

Bronchogen

—

Retatrutide

·MTC personal or family history (presumed class effect)
·Pregnancy / breastfeeding

Relative Contraindications

Bronchogen

—

Retatrutide

·Severe gastroparesis
·History of pancreatitis
·Severe cardiovascular disease (HR signal)

05Administration Protocol

Parameter

Bronchogen

Retatrutide

1. Research context only

Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.

Investigational peptide. Research vials reconstituted with bacteriostatic water per label.

2. Animal model protocol

In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017 Kuzubova 2015

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Organotypic culture

Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006

Once weekly, same day.

4. Khavinson bioregulator tradition

Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.

Refrigerate 2–8 °C. Light-protected.

5. Needle

—

27–31G, 4–8 mm insulin syringe.